Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2025-04-23 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 91% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing changes in issued shares (including share option exercises) and treasury share transactions (share buybacks) of Ascletis Pharma. It reports on both issues of new shares and repurchases/cancellations, fitting the definition of a Transaction in Own Shares (POS) rather than an earnings release, capital raise, or full report. Hence, the correct classification is POS.
2025-04-23 English
INSIDE INFORMATION - ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS OF U.S. PHASE IB MULTIPLE ASCENDING DOSE STUDY OF SMALL MOLECULE ORAL GLP-1R AGONIST ASC30 AND SUBMISSION OF 13-WEEK PHASE IIA STUDY PR
Regulatory Filings Classification · 85% confidence The document is an "Inside Information" announcement under HKEX Listing Rules disclosing positive Phase Ib clinical study topline results and submission of a Phase IIa protocol. It does not present financial statements, management changes, voting results, dividends, or merger activity, nor is it a formal report like an interim or annual report. It is a regulatory announcement of material proprietary information and thus falls into the general regulatory announcements/fallback category (RNS).
2025-04-23 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 85% confidence The document is Hong Kong Exchange Form FF305 “Next Day Disclosure Return” under Main Board Rule 13.25A/GEM Rule 17.27A. It details changes in the company’s own share capital — share issuances (upon exercise of share options) and on-market repurchases of treasury shares. This is not an earnings release, annual report, director dealing, or AGM material. It is a regulatory disclosure of the company’s transactions in its own shares. Thus it fits “Transaction in Own Shares (POS).”
2025-04-17 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 85% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Listing Rules, detailing both the issue of new shares on exercise of share options and on-market repurchases of treasury shares. It is a transaction report covering the company buying back its own shares and issuing shares from treasury, which falls squarely under the “Transaction in Own Shares” category. It is neither a simple announcement of a full report nor an AGM material, but a detailed regulatory disclosure of share transactions.
2025-04-16 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) reporting detailed changes in issued shares and treasury shares (share options exercised, share issues, and share repurchases) pursuant to the Main Board and GEM listing rules. It provides numbers of shares issued, repurchased, average prices per share, opening and closing balances – a clear report of the company’s transactions in its own shares. This aligns with the “Transaction in Own Shares” category.
2025-04-15 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 88% confidence The document is a Hong Kong Stock Exchange Form FF305 “Next Day Disclosure Return” detailing changes in issued shares and treasury shares, including exercise of share options (new issuance) and share repurchases. It is not an earnings release, annual report, or management presentation, but a regulatory disclosure of share transactions by the company. This corresponds to the “Transaction in Own Shares” category (Code POS).
2025-04-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.